Renin-Angiotensin-Aldosterone System Inhibitors: Recommendations e390 Recommendations for Lipid Management e390 8.4. Nitrates e391 Calcium Channel Blockers e391 8.6. Oxygen e391 Analgesics: Morphine, Nonsteroidal Anti-inflamma- tory Drugs, and Cyclooxygenase II Inhibitors e391 9. Complications After STEMI e391 9.1. Cardiogenic Shock e391 Treatment of Cardiogenic Shock: Recommendations e391 9.2. Severe HF e392 9.3. RV Infarction e392 9.4. Mechanical Complications e392 9.4.1. Diagnosis e392 9.4.2. Mitral Regurgitation e392 Ventricular Septal Rupture e392 LV Free-Wall Rupture e393 9.4.5. LV Aneurysm e393 Electrical Complications During the Hospital Phase of STEMI e393 9.5.1. Ventricular Arrhythmias e393 9.5.2. Implantable Cardioverter-Defibrillator Therapy Before Discharge e393 AF and Other Supraventricular Tachyarrhythmias e393 Bradycardia, AV Block, and Intraventricular Conduction Defects e394 Pacing in STEMI: Recommendation e394 9.6. Pericarditis e394 Management of Pericarditis After STEMI: Recommendations e394 9.7. Thromboembolic and Bleeding Complications . e395 9.7.1. Thromboembolic Complications e395 Anticoagulation: Recommendations e395 Heparin-Induced Thrombocytopenia e395 9.7.2. Bleeding Complications e395 Treatment of ICH e396 Vascular Access Site Bleeding . e396 Acute Kidney Injury e397 Hyperglycemia e397 10. Risk Assessment After STEMI e397 Use of Noninvasive Testing for Ischemia Before Discharge: Recommendations e397 Assessment of LV Function: Recommendation . e398 Assessment of Risk for SCD: Recommendation e398 Posthospitalization Plan of Care e399 Posthospitalization Plan of Care: Recommendations e399 The Plan of Care for Patients With STEMI e399 Smoking Cessation e399 Cardiac Rehabilitation e399 Systems of Care to Promote Care Coordination e399 Unresolved Issues and Future Research Directions e401 12.1. Patient Awareness e401 Regional Systems of Care e401 Transfer and Management of Non High-Risk Patients After Administration of Fibrinolytic Therapy e401 12.4. Antithrombotic Therapy e401 12.5. Reperfusion Injury e401 Approach to Noninfarct Artery Disease e401 Prevention of SCD e402 Prevention of HF e402 References e402 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e419 Appendix 2. 